Newsletters
Medications such as Ozempic and Wegovy, initially developed for managing Type 2 diabetes, are now under increased scrutiny as their popularity for weight loss surges.
These drugs, which act by mimicking the GLP-1 hormone found naturally in the body, are designed to enhance insulin secretion, delay stomach emptying and create a prolonged feeling of fullness.
While their appetite-suppressing effects have made them a go-to option for shedding pounds, medical professionals are voicing growing concerns over possible adverse effects, especially as these treatments extend beyond their original purpose. The expanding off-label use has intensified calls for more rigorous evaluation of its long-term impact on health.
1 min read
A recent study from the United States has revealed that approximately 10% of American adults are using weight-loss medications such as Ozempic.
Marketed under the name Wegovy for weight management, Ozempic is gaining attention not only for its effectiveness but also for its side effects. The most commonly reported issues include nausea, diarrhea, and various other gastrointestinal problems, prompting growing concern among healthcare professionals.
The most pressing concern, however, centers on serious health conditions linked to extended use of these medications. Dr. Penny Ward from King’s College London warns that long-term users may face heightened risks of pancreatitis and musculoskeletal damage. In some reported cases, complications have been life-threatening, prompting renewed calls for stricter oversight and in-depth clinical follow-up.
2 min read
